A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
David McMullin,1 David Clark,1 Bill Cavanagh,1 Paul Karpecki,2 Todd C Brady1 1Aldeyra Therapeutics, Inc, Lexington, MA, USA; 2Kentucky Eye Institute, Lexington, KY, USACorrespondence: Todd C BradyAldeyra Therapeutics, Inc, 131 Hartwell Avenue, Suite 320, Lexington, MA, 02421, USATel +1 781 761-4904E...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8ed6c8cfce4d4c78970537ad6781fa01 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|